Search Results

You are looking at 91 - 100 of 285 items for :

  • "neutropenia" x
Clear All
Full access

Erin Reid, Gita Suneja, Richard F. Ambinder, Kevin Ard, Robert Baiocchi, Stefan K. Barta, Evie Carchman, Adam Cohen, Oxana V. Crysler, Neel Gupta, Chelsea Gustafson, Allison Hall, Kimberly L. Johung, Ann Klopp, Ann S. LaCasce, Chi Lin, Amitkumar Mehta, Manoj P. Menon, David Morgan, Nitya Nathwani, Ariela Noy, Lee Ratner, Stacey Rizza, Michelle A. Rudek, Julian Sanchez, Jeff Taylor, Benjamin Tomlinson, Chia-Ching J. Wang, Sai Yendamuri, Mary A. Dwyer, CGC and Deborah A. Freedman-Cass

malignancies). 39 – 43 In particular, chemotherapy can cause neutropenia, which is a major risk factor for the development of infections. 44 Newer targeted agents are also associated with immunosuppression and increased infection risk. 45 The frequency and

Full access

Ryan D. Gentzler and Jyoti D. Patel

significant differences in survival were seen among the 4 regimens. Patients receiving carboplatin and paclitaxel had a lower incidence of grade 3 and 4 nausea, vomiting, and febrile neutropenia. From this point on, carboplatin and paclitaxel became the most

Full access

William J. Gradishar

monitor WBC counts in patients receiving palbociclib and ribociclib, but those who develop neutropenia “generally don't feel the effects” and febrile neutropenia is uncommon, he indicated. “As we move forward,” he added, clinicians can expect “the coming

Full access

Andrew D. Zelenetz

(PFS) and complete response (CR) rate. However, BR was associated with lower rates of neutropenia and severe infections in elderly patients, suggesting that it may be considered as an alternative first-line regimen in fit, elderly patients. Long

Full access

Andrew D. Zelenetz

indicated. Indications for therapy for TLGLL include severe neutropenia (absolute neutrophil count <0.5 x 10 9 /L), moderate neutropenia with recurrent infections, symptomatic or transfusion-dependent anemia, autoimmune disorders associated with TLGLL, and B

Full access

Angela M. Davies, Philip C. Mack, Primo N. Lara Jr., Derick H. Lau, Kathleen Danenberg, Paul H. Gumerlock and David R. Gandara

. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis . Cancer Res 2000 ; 60 : 6921 – 6926 . 26 Innocenti F Undevia SD Iyer L . UGT1A1*28 polymorphism is a predictor of neutropenia in irinotecan

Full access

Peter MD, PhD Burns Jennifer L. Pluchino Lenora PhD 12 2017 15 15 12 12 1520 1520 1541 1541 10.6004/jnccn.2017.0175 A Patient Risk Model of Chemotherapy-Induced Febrile Neutropenia: Lessons Learned From the ANC Study Group Lyman

Full access

of Chemotherapy-Induced Neutropenia: Measuring Quality, Cost, and Value Dinan Michaela A. a b PhD Hirsch Bradford R. a b MD, MBA Lyman Gary H. c d MD, MPH 1 2015 13 13 1 1 e1 e1 e7 e7 01300e1 10.6004/jnccn.2015.0014

Full access

12 12 11 11 1561 1561 1568 1568 jnccn0121561 10.6004/jnccn.2014.0156 Timing of Initial Antibiotic Treatment for Febrile Neutropenia in the Emergency Department: The Need for Evidence-Based Guidelines Kyriacou Demetrios N. a b MD, PhD Jovanovic

Full access

Apar Kishor Ganti, Mollie deShazo, Alva B. Weir III and Arti Hurria

concurrent chemotherapy and radiation. They found that although acute toxicities (esophagitis and neutropenia) were higher in older patients, no differences were seen in long-term toxicity or overall survival based on age. In a similar analysis, Schild et al